How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/secondary-malignant-neoplasm-of-pancreas.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Secondary malignant neoplasm of pancreas — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Secondary malignant neoplasm of pancreas (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Secondary malignant neoplasm of pancreas, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Camptosar	irinotecan	Pfizer	Topoisomerase Inhibitor	topoisomerase I	1996-01-01
Camptosar	Irinotecan Hydrochloride	Pfizer	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Camptosar	onivyde	Pfizer	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Taxol	nab-paclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Taxol	paclitaxel	Pfizer	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	Taxol	M.D. Anderson Cancer Center		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5
Abraxane	Abraxane	The First Affiliated Hospital with Nanjing Medical University		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5
Taxol	Nabpaclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 6 drugs in Secondary malignant neoplasm of pancreas
M.D. Anderson Cancer Center · 1 drug in Secondary malignant neoplasm of pancreas
The First Affiliated Hospital with Nanjing Medical University · 1 drug in Secondary malignant neoplasm of pancreas

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Secondary malignant neoplasm of pancreas:

Cite this brief

Drug Landscape (2026). Secondary malignant neoplasm of pancreas — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/secondary-malignant-neoplasm-of-pancreas. Accessed 2026-06-10.

Secondary malignant neoplasm of pancreas full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing